ストックスクリーナーアプリを入手
1.33
0.76%
0.01
前日終値:
$1.32
開ける：
$1.3
24時間の取引高:
434.73K
Relative Volume:
0.58
時価総額：
$95.94M
収益：
-
当期純損益:
$-292.19M
株価収益率:
-0.293
EPS:
-4.54
ネットキャッシュフロー:
$-208.41M
1週間 パフォーマンス:
+3.91%
1か月 パフォーマンス:
-13.64%
6か月 パフォーマンス:
+11.76%
1年 パフォーマンス:
-66.33%
1日の値動き範囲:
$1.282
$1.36
1週間の範囲:
$1.25
$1.41
52週間の値動き範囲:
$1.01
$4.00
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
名前
Zentalis Pharmaceuticals Inc
セクター
電話
(858) 263-4333
住所
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
ZNTL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.33 | 95.37M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-12 | アップグレード | Wedbush | Underperform → Neutral |
| 2024-06-20 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-18 | ダウングレード | Jefferies | Buy → Hold |
| 2024-06-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | ダウングレード | Wedbush | Neutral → Underperform |
| 2024-06-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-11-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | 開始されました | Cowen | Outperform |
| 2022-04-06 | 開始されました | Wells Fargo | Overweight |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-29 | 開始されました | Oppenheimer | Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-01-20 | 開始されました | Wedbush | Outperform |
| 2020-09-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-28 | 開始されました | Guggenheim | Buy |
| 2020-04-28 | 開始されました | Jefferies | Buy |
| 2020-04-28 | 開始されました | Morgan Stanley | Overweight |
| 2020-04-28 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Zentalis Pharmaceuticals Inc (ZNTL) 最新ニュース
Why analysts upgrade Zentalis Pharmaceuticals Inc. stockJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - newser.com
Why Zentalis Pharmaceuticals Inc. stock is in analyst buy zone2025 Dividend Review & Weekly Top Gainers Alerts - newser.com
Is Zentalis Pharmaceuticals Inc. stock in correction or buying zoneJuly 2025 Price Swings & Consistent Growth Equity Picks - newser.com
Zentalis Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
What indicators show strength in Zentalis Pharmaceuticals Inc.Portfolio Gains Report & Daily Risk Controlled Trade Plans - newser.com
Can Zentalis Pharmaceuticals Inc. stock reach $100 price target2025 Historical Comparison & Entry Point Strategy Guides - newser.com
How geopolitical tensions affect Zentalis Pharmaceuticals Inc. stockEarnings Overview Summary & Consistent Growth Stock Picks - newser.com
Is Zentalis Pharmaceuticals Inc. forming a bottoming baseMarket Performance Report & Weekly Return Optimization Plans - newser.com
Morgan Stanley Maintains Zentalis Pharmaceuticals (ZNTL) Equal-Weight Recommendation - MSN
Relative strength of Zentalis Pharmaceuticals Inc. in sector analysisPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
ZNTL Stock Update: Morgan Stanley Lowers Price Target by 50% | Z - GuruFocus
What recovery options are there for Zentalis Pharmaceuticals Inc.2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
Zentalis Pharmaceuticals Reports Q3 2025 Financial Results - TipRanks
Zentalis Pharmaceuticals stock price target lowered to $2 at Leerink Partners - Investing.com Canada
Zentalis Pharmaceuticals Cuts Losses And Draws Analyst Support - Finimize
Zentalis (ZNTL) Progresses DENALI Trial for Ovarian Cancer Treat - GuruFocus
Zentalis Pharmaceuticals Q3 net loss narrows - MarketScreener
[8-K] Zentalis Pharmaceuticals, Inc. Reports Material Event | ZNTL SEC FilingForm 8-K - Stock Titan
Zentalis (Nasdaq: ZNTL) DENALI Phase 2 on track; topline data anticipated by end 2026 - Stock Titan
Multi asset correlation models including Zentalis Pharmaceuticals Inc.Trend Reversal & Daily Stock Momentum Reports - newser.com
How Zentalis Pharmaceuticals Inc. stock benefits from strong dollar2025 Short Interest & Daily Volume Surge Trade Alerts - newser.com
Zentalis Pharmaceuticals Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
Zentalis Pharmaceuticals Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Why Zentalis Pharmaceuticals Inc. stock remains undervaluedJuly 2025 Drop Watch & Daily Profit Focused Stock Screening - newser.com
Can Zentalis Pharmaceuticals Inc. rally from current levelsJuly 2025 Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Can Zentalis Pharmaceuticals Inc. stock beat market expectations this quarterMarket Growth Report & Fast Moving Stock Trade Plans - newser.com
Will Zentalis Pharmaceuticals Inc. stock keep outperforming rivalsPortfolio Return Report & Real-Time Stock Movement Alerts - newser.com
Zentalis Pharmaceuticals Inc (ZNTL) 財務データ
収益
当期純利益
現金流量
EPS
Zentalis Pharmaceuticals Inc (ZNTL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
1.43%
0.07%
大文字化:
|
ボリューム (24 時間):